Linagliptin/Empagliflozin

利格列汀/恩格列净

Report date: 2026/03/23 20:03:44

Base Information

Drug NameLinagliptin/Empagliflozin
Drug Alias NameLinagliptin and Empagliflozin恩格列净•利格列汀Empagliflozin/Linagliptin恩格列净和利格列汀恩格列净/利格列汀 +[19] 
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsDipeptidyl peptidase IVSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Cardiovascular Diseases
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/01/30
Country/TerritoryBulgariaCanadaUnited States +[25] 
CombinationsYes LinagliptinEmpagliflozin
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgHumanis Saglık Anonim SirketiBoehringer Ingelheim International Gmbh +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Cardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeA10BD19
Related LinksWikipediaKEGG